In May 2026, NIH researchers published a study in Nature Metabolism revealing new details about how semaglutide actually works inside neurons. The findings explain why patients respond differently to GLP-1 medications — and point toward ways to enhance the effect.
The Discovery
The research, conducted in mice, focused on GLP-1 receptor-expressing neurons in the area postrema — a brain region involved in appetite regulation and nausea. Scientists found that semaglutide triggers weight loss through a specific signaling molecule called cAMP (cyclic adenosine monophosphate) within these neurons.
The key insight: not all GLP-1-receptor neurons respond the same way. Some cells maintained sustained elevated cAMP levels in the presence of semaglutide, producing ongoing appetite suppression. Other neurons experienced only temporary increases because they internalized or degraded their GLP-1 receptors.
Why Some Patients Respond Better Than Others
This cellular-level variation likely explains a clinical puzzle: why approximately 15-20% of patients are "non-responders" who lose minimal weight on GLP-1 medications. If a patient's neurons disproportionately internalize their GLP-1 receptors after drug exposure, the appetite-suppressing effect diminishes faster.
The researchers demonstrated that by inhibiting PDE4 — an enzyme that degrades cAMP — they could shift neurons toward a sustained response. The drug they used, roflumilast, is already FDA-approved for COPD. While this combination hasn't been tested for weight loss in humans, it represents a potential pathway to enhance GLP-1 efficacy for non-responders.
What This Means for Patients
This research is pre-clinical — it doesn't change treatment recommendations today. But it validates two things patients already experience: first, that response to GLP-1 medications varies genuinely between people (it's not about effort or compliance), and second, that the plateau many patients experience may have a biological mechanism that could eventually be targeted.
Practical Takeaway
If you're on a GLP-1 and it's working, this research confirms you're among the majority whose neurons respond well. If you've tried one GLP-1 with limited results, switching to a different agent (semaglutide to tirzepatide, or vice versa) may recruit different neural pathways. Discuss options with your provider.
Sunlight $159/mo sema, $239/mo tirz · LegitScript certified. Flat pricing — $159 first month, $179 ongoing (semaglutide). No membership, free shipping, HSA/FSA.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
Embody From $149/mo · Injectable semaglutide with coaching included. LegitScript-certified 503B pharmacy sourcing. Strong onboarding support.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.